[Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review]

T cell adoptive therapy using chimeric antigen receptor T (CAR-T) cells has emerged as a novel strategy for the treatment of cancer. CAR-T cells kill tumor cells independent on the major histocompatibility complex (MHC), which has already achieved impressive progression in the treatment of blood malignancies. Nonetheless, in the treatment of solid tumors, CAR-T cell therapy has problems of easy off-target and inefficient treatment. The rapid development of synthetic biology has greatly enhanced the enthusiasm of CAR-T designers. In this review, we present discussions around current constraints on CAR-T cell therapy in the treatment of solid tumor and cutting-edge progress of new-type CAR-T cell armed with synthetic biology. Moreover, the preclinical studies and clinical trials of several solid tumor targets with a wide range of applications are described in detail.